Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$435M |
| 2 |
Amazon
AMZN
|
+$334M |
| 3 |
Moderna
MRNA
|
+$53.9M |
| 4 |
Linde
LIN
|
+$44.2M |
| 5 |
DTE Energy
DTE
|
+$43.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 1000 Value ETF
IWD
|
+$63.6M |
| 2 |
Comcast
CMCSA
|
+$39.7M |
| 3 |
Evergy
EVRG
|
+$38.5M |
| 4 |
Public Service Enterprise Group
PEG
|
+$38.4M |
| 5 |
Bio-Techne
TECH
|
+$30.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.37% |
| 2 | Consumer Discretionary | 10.36% |
| 3 | Financials | 7.14% |
| 4 | Industrials | 6.8% |
| 5 | Healthcare | 6.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1601
StoneX
SNEX
$8.25B
| $374K | ﹤0.01% |
+31,241
| New | +$404K |
|
1602
Conduent
CNDT
$257M
| $373K | ﹤0.01% |
49,744
-25,390
| -34% | -$185K |
|
|
PRTK
1603
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $373K | ﹤0.01% |
+54,728
| New | +$442K |
|
1604
Chord Energy
CHRD
$7.77B
| $371K | ﹤0.01% |
3,694
-74,673
| -95% | -$6.14M |
|
1605
Materion
MTRN
$4.91B
| $371K | ﹤0.01% |
4,923
-6,766
| -58% | -$501K |
|
1606
Puma Biotechnology
PBYI
$469M
| $370K | ﹤0.01% |
40,331
-18,619
| -32% | -$189K |
|
1607
Precigen
PGEN
$2.67B
| $370K | ﹤0.01% |
56,725
+27,751
| +96% | +$194K |
|
1608
Sibanye-Stillwater
SBSW
$8.58B
| $370K | ﹤0.01% |
+22,142
| New | +$411K |
|
1609
X4 Pharmaceuticals
XFOR
$417M
| $370K | ﹤0.01% |
+1,896
| New | +$477K |
|
1610
Cars.com
CARS
$643M
| $368K | ﹤0.01% |
25,681
+6,104
| +31% | +$84.8K |
|
|
GPMT
1611
Granite Point Mortgage Trust
GPMT
$50.1M
| $368K | ﹤0.01% |
+24,974
| New | +$345K |
|
1612
Grid Dynamics Holdings
GDYN
$621M
| $367K | ﹤0.01% |
+24,415
| New | +$382K |
|
1613
NovaGold Resources
NG
$4.18B
| $367K | ﹤0.01% |
+45,839
| New | +$432K |
|
1614
Tucows
TCX
$103M
| $366K | ﹤0.01% |
4,552
+1,535
| +51% | +$122K |
|
1615
Vanda Pharmaceuticals
VNDA
$319M
| $366K | ﹤0.01% |
17,034
-37,368
| -69% | -$669K |
|
|
BFX
1616
DELISTED
BowFlex Inc.
BFX
| $366K | ﹤0.01% |
21,730
-64,431
| -75% | -$1.09M |
|
1617
Lakeland Industries
LAKE
$117M
| $365K | ﹤0.01% |
+16,366
| New | +$422K |
|
|
SILV
1618
DELISTED
SilverCrest Metals Inc. Common Shares
SILV
| $365K | ﹤0.01% |
41,851
-89,852
| -68% | -$822K |
|
1619
Liberty Global Class C
LBTYK
$3.56B
| $364K | ﹤0.01% |
+13,454
| New | +$363K |
|
|
MCFE
1620
DELISTED
McAfee Corp. Class A Common Stock
MCFE
| $364K | ﹤0.01% |
12,982
-3,031
| -19% | -$77.7K |
|
1621
Cytosorbents Corp
CTSO
$22.6M
| $363K | ﹤0.01% |
+48,071
| New | +$405K |
|
1622
DoorDash
DASH
$103B
| $363K | ﹤0.01% |
+2,036
| New | +$299K |
|
1623
MINISO
MNSO
$3.42B
| $363K | ﹤0.01% |
17,457
-220,910
| -93% | -$5.3M |
|
|
NOTV
1624
DELISTED
Inotiv
NOTV
| $363K | ﹤0.01% |
+13,587
| New | +$340K |
|
1625
Verra Mobility
VRRM
$667M
| $362K | ﹤0.01% |
23,547
-189,125
| -89% | -$2.75M |
|
Similar funds
Michael Gelband's Q2 2021 Portfolio in Review
As of Q2 2021, Michael Gelband held 3,092 positions worth $9.04B, up 32% from $6.86B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Michael Gelband deployed $1.88B of net new capital in Q2 2021, opening 1,032 new positions and adding to 581 existing holdings. Its largest new stake was Linde: 151,692 shares worth $43.9M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was iShares Russell 1000 Value ETF, an estimated $63.6M trimmed.
- Michael Gelband's largest Q2 2021 buy was Linde: 151,692 shares worth $43.9M.
- Michael Gelband added most to Microsoft in Q2 2021, an estimated $435M increase.
- Michael Gelband's biggest Q2 2021 reduction was iShares Russell 1000 Value ETF, cutting an estimated $63.6M.
- Michael Gelband fully exited Charles River Laboratories in Q2 2021, selling an estimated $27.9M.
- Michael Gelband's ten largest holdings make up 35% of its $9.04B portfolio in Q2 2021.
- Michael Gelband opened 1,032 new positions and closed 820 in Q2 2021.
- Michael Gelband's portfolio value rose 32% quarter-over-quarter to $9.04B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.